Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single Arm Study With CABozantinib in Non-Small Cell Lung Cancer Patients With MET Deregulation

NCT03911193 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.

NCT NCT03911193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03911193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single Arm Study With CABozantinib in Non-Small Cell Lung Cancer Patients With MET Deregulation
Lead sponsor
Fondazione Ricerca Traslazionale
Phase
Phase 2
Overall status
Unknown status
Start date
September 21, 2018
Completion date
September 30, 2020
Enrollment
25 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer